Ligand id: 9640

Name: rontalizumab

Immunopharmacology Comments
The rationale for targeting IFNα in SLE, and outcomes from anti-IFNα or anti-type I interferon receptor (IFNAR1) antibody therapies in SLE patients is discussed by Kalunian (2016) [3].
Immunopharmacology Disease
Disease X-Refs Comment References
Systemic lupus erythematosus Disease Ontology: DOID:9074
OMIM: 152700
Orphanet: ORPHA536
Failed Phase 2 clinical candidate for SLE.